Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Enhanced Cohort methods for HIV Research and Epidemiology (ENCORE) in the United States

Award Number: R01AI172092
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/09/2022
PERIOD OF PERFORMANCE END DATE: 12/31/2027

Group Awards By:

View Award Description

Enhanced Cohort methods for HIV Research and Epidemiology (ENCORE) in the United States - In the United States, women are prioritized in the US national strategy to end the epidemic. Multiple individual, interpersonal, and structural vulnerabilities fuel the HIV epidemic among women, and worsen health conditions (e.g., substance use and mental health disorders). National cohorts are critical to monitoring epidemic trends and how major events (e.g., epidemics, new biomedical interventions) impact HIV and other health conditions. The objective of this proposal is to use a novel, hybrid “community hub”-supported digital cohort (“hub-supported digital cohort”) model to evaluate HIV incidence, risk factors, and health conditions among women in the US (N=3,000). In this model, on-the-ground community “hubs” will support enrollment and retention of a nationwide digital cohort. We will refine optimal digital cohort methods while examining the impact of structural and psychosocial syndemic experiences on HIV incidence and parameterizing mathematical models to identify targets for future multi-level combination HIV prevention interventions. The specific aims are: 1) Determine the efficiency and acceptability of using a novel, hub-supported digital cohort model to enroll and retain a sample of women for HIV research. 2) Estimate the prevalence and characterize patterns of co-occurring health conditions among women. 3) Estimate HIV incidence in women, followed every 6 months for at least 24 months to identify tailored approaches for combination, multi-disciplinary HIV prevention interventions. 3.1) Examine the effect of co-occurring health conditions on HIV incidence among women in the US. 3.2) Characterize the PrEP continuum among women and associations with HIV incidence over time, including uptake of newly emerging formulations, longitudinal patterns of HIV risk and adherence, and the role of co-occurring health conditions in the PrEP continuum PrEP uptake, adherence, and retention. 4.) Develop dynamic models of multi-level combination HIV prevention interventions and scale-up among women to simulate the impact of evaluated interventions on HIV incidence through 2030, corresponding to the National HIV strategy. There is a need to refine and evaluate hybrid digital cohort models with attention to mitigating selection bias and attrition of different populations – an important area of research. Our explicit efforts to develop a hybrid cohort model center on a focus to support research participation across different populations and provide representative and generalizable data. Study findings will provide critical epidemiologic parameters for future HIV prevention research, provide a platform for exploration of other research questions, and inform the development of evidence-based and acceptable HIV interventions to reduce HIV acquisition among women in the US. Public Health Statement Women are highly burdened by the HIV epidemic in the United States. This proposal will use a novel, technology-infused “community hub”-supported digital cohort (“hub-supported digital cohort”) model to evaluate HIV incidence, co-occurring health conditions, and risk factors among women in the US and Puerto Rico. We will refine optimal digital cohort methods, gather 24 months of longitudinal data from women, examine individual and contextual predictors of HIV incidence, and utilize cohort and contextual data to parameterize mathematical models for the identification of effective HIV prevention interventions to change the trajectory of HIV and co-occurring health conditions among women in the US.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Allergy and Infectious Diseases Research	001	4	2/19/2026	NON-COMPETING CONTINUATION	$0
2026	2025	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Allergy and Infectious Diseases Research	000	4	12/4/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $1,757,144 )
2025	2025	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Allergy and Infectious Diseases Research	003	4	9/12/2025	NON-COMPETING CONTINUATION	$1,757,144
2025	2024	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Allergy and Infectious Diseases Research	001	3	7/23/2025	OTHER REVISION	$0
2025	2024	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Allergy and Infectious Diseases Research	002	3	8/4/2025	OTHER REVISION	$0
2025	2024	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Allergy and Infectious Diseases Research	000	3	3/21/2025	TERMINATION	$0
														Subtotal = $1,757,144

Issue Date FY: 2024 ( Subtotal = $1,761,882 )
2024	2024	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Allergy and Infectious Diseases Research	000	3	7/16/2024	NON-COMPETING CONTINUATION	$1,761,882
														Subtotal = $1,761,882

Issue Date FY: 2023 ( Subtotal = $1,775,562 )
2023	2023	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Allergy and Infectious Diseases Research	001	2	9/1/2023	NON-COMPETING CONTINUATION	$0
2023	2023	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Allergy and Infectious Diseases Research	000	2	7/11/2023	NON-COMPETING CONTINUATION	$1,775,562
														Subtotal = $1,775,562

Issue Date FY: 2022 ( Subtotal = $1,762,325 )
2022	2022	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Allergy and Infectious Diseases Research	000	1	8/10/2022	NEW	$1,762,325
														Subtotal = $1,762,325

Grand Total All Awards = $7,056,913

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Enhanced Cohort methods for HIV Research and Epidemiology (ENCORE) in the United States

Award Number: R01AI172092

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/09/2022

PERIOD OF PERFORMANCE END DATE: 12/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer